The emerging potential of the apelin-APJ system in heart failure

Journal of Cardiac Failure

Volumn 21, Issue 6, 2015, Pages 489-498

  Dalzell, Jonathan R ^a,b   Rocchiccioli, John P ^a   Weir, Robin A P ^c   Jackson, Colette E ^a,b   Padmanabhan, Neal ^d   Gardner, Roy S ^b   Petrie, Mark C ^b   McMurray, John J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

^c HAIRMYRES HOSPITAL   (United Kingdom)

^d WESTERN INFIRMARY   (United Kingdom)

Author keywords

Apelin; APJ; heart failure; neurohormone; pathophysiology

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; APELIN; APELIN RECEPTOR; NEUROHORMONE; TUMOR NECROSIS FACTOR ALPHA; APLNR PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR;

ADIPOSE TISSUE; ANTIHYPERTENSIVE ACTIVITY; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR SYSTEM; DRUG TARGETING; GENE EXPRESSION; HEART FAILURE; HEART PROTECTION; HOMEOSTASIS; HUMAN; HYPOXIA; INOTROPISM; ISCHEMIA; MOLECULAR BIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TISSUE METABOLISM; VASOCONSTRICTION; VASODILATATION; ANIMAL; DOWN REGULATION; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; DOWN-REGULATION; HEART FAILURE; HUMANS; RECEPTORS, G-PROTEIN-COUPLED; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 84930396966     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2015.03.007     Document Type: Review

References (97)

1. A. Mosterd, and A.W. Hoes Clinical epidemiology of heart failure Heart 93 2007 1137 1146
2. C. Berry, D.R. Murdoch, and J.J. McMurray Economics of chronic heart failure Eur J Heart Fail 3 2001 283 291
3. P.S. Jhund, K. Macintyre, and C.R. Simpson Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people Circulation 119 2009 515 523
4. K. Tatemoto, M. Hosoya, and Y. Habata Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor Biochem Biophys Res Commun 251 1998 471 476
5. M. Hosoya, Y. Kawamata, and S. Fukusumi Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin J Biol Chem 275 2000 21061 21067
6. J.J. Maguire, M.J. Kleinz, S.L. Pitkin, and A.P. Davenport [Pyr1]Apelin-13 identified as the predominant apelin isoform in the human heart. vasoactive mechanisms and inotropic action in disease Hypertension 54 2009 598 604
7. E.Y. Zhen, R.E. Higgs, and J.A. Gutierrez Pyroglutamyl apelin-13 identified as the major apelin isoform in human plasma Anal Biochem 442 2013 1 9
8. M.J. Kleinz, and A.P. Davenport Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells Regul Pept 118 2004 119 125
9. M.M. Chen, E.A. Ashley, and D.X. Deng Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction Circulation 108 2003 1432 1439
10. G. Földes, F. Horkay, and I. Szokodi Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure Biochem Biophys Res Commun 308 2003 480 485
11. J. Boucher, B. Masri, and D. Daviaud Apelin, a newly identified adipokine up-regulated by insulin and obesity Endocrinology 146 2005 1764 1771
12. B.F. O'Dowd, M. Heiber, and A. Chan A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11 Gene 136 1993 355 360
13. S.D. Katugampola, J.J. Maguire, S.R. Matthewson, and A.P. Davenport [125I]-(Pyr1) Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man Br J Pharmacol 132 2001 1255 1260
14. M.J. Kleinz, J.N. Skepper, and A.P. Davenport Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells Regul Pept 126 2005 233 240
15. K. Kuba, L. Zhang, and Y. Imai Impaired heart contractility in apelin gene-deficient mice associated with aging and pressure overload Circ Res 101 2007 e32 42
16. W. Wang, S.M. McKinnie, and V.B. Patel Loss of apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic apelin analogues J Am Heart Assoc 2 2013 e000249
17. Y.X. Jia, Z.F. Lu, and J. Zhang Apelin activates L-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas Peptides 28 2007 2023 2029
18. A. Salcedo, J. Garijo, and L. Monge Apelin effects in human splanchnic arteries. Role of nitric oxide and prostanoids Regul Pept 144 2007 50 55
19. A.G. Japp, N.L. Cruden, and D.A. Amer Vascular effects of apelin in vivo in man J Am Coll Cardiol 52 2008 908 913
20. M.J. Kleinz, and A.P. Davenport Emerging roles of apelin in biology and medicine Pharmacol Ther 107 2005 198 211
21. X. Han, D.L. Zhang, D.X. Yin, Q.D. Zhang, and W.H. Liu Apelin-13 deteriorates hypertension in rats after damage of the vascular endothelium by ADMA Can J Physiol Pharmacol 91 2013 708 714
22. S.L. Pitkin, J.J. Maguire, R.E. Kuc, and A.P. Davenport Modulation of the apelin/APJ system in heart failure and atherosclerosis in man Br J Pharmacol 160 2010 1785 1795
23. B. Gurzu, B.C. Petrescu, M. Costuleanu, and G. Petrescu Interactions between apelin and angiotensin II on rat portal vein J Renin Angiotensin Aldosterone Syst 7 2006 212 216
24. T. Hashimoto, M. Kihara, and J. Ishida Apelin stimulates myosin light chain phosphorylation in vascular smooth muscle cells Arterioscler Thromb Vasc Biol 26 2006 1267 1272
25. D.K. Lee, R. Cheng, and T. Nguyen Characterization of apelin, the ligand for the APJ receptor J Neurochem 74 2000 34 41
26. J. Ishida, T. Hashimoto, and Y. Hashimoto Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo J Biol Chem 279 2004 26274 26279
27. K. Tatemoto, K. Takayama, and M.X. Zou The novel peptide apelin lowers blood pressure via a nitric oxide dependent mechanism Regul Pept 99 2001 87 92
28. C.J. Charles, M.T. Rademaker, and A.M. Richards Apelin-13 induces a biphasic haemodynamic response and hormonal activation in normal conscious sheep J Endocrinol 189 2006 701 710
29. K. Nagano, J. Ishida, M. Unno, T. Matsukura, and A. Fukamizu Apelin elevates blood pressure in ICR mice with LNAME-induced endothelial dysfunction Mol Med Rep 7 2013 1371 1375
30. A.G. Japp, N.L. Cruden, and G. Barnes Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure Circulation 121 2010 1818 1827
31. G.D. Barnes, S. Alam, and G. Carter Sustained cardiovascular actions of APJ agonism during renin-angiotensin system activation and in patients with heart failure Circ Heart Fail 6 2013 482 491
32. N. de Mota, A. Reaux-le Goazigo, and S. El Messari Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release Proc Natl Acad Sci U S A 101 2004 10464 10469
33. A. Reaux, N. de Mota, and I. Skultetyova Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain J Neurochem 77 2001 1085 1096
34. A. Hus-Citharel, N. Bouby, A. Frugière, L. Bodineau, J.M. Gasc, and C. Llorens-Cortes Effect of apelin on glomerular hemodynamic function in the rat kidney Kidney Int 74 2008 486 494
35. K.V. Ernst, E.A. Ashley, and D. Charo Apelin regulates cardiac contractility and rescues neurohormonal heart failure [abstract] Circulation 114 2006 II-66
36. M. Azizi, X. Iturrioz, and A. Blanchard Reciprocal regulation of plasma apelin and vasopressin by osmotic stimuli J Am Soc Nephrol 19 2008 1015 1024
37. I. Szokodi, P. Tavi, and G. Foldes Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates contractility Circ Res 91 2002 434 440
38. K. Farkasfalvi, M.A. Stagg, and S.R. Coppen Direct effects of apelin on cardiomyocyte contractility and electrophysiology Biochem Biophys Res Commun 357 2007 889 895
39. Á. Perjés, R. Skoumal, and O. Tenhunen Apelin increases cardiac contractility via protein kinase Cε- and extracellular signal-regulated kinase-dependent mechanisms PLoS One 9 2014 e93473
40. M.F. Berry, T.J. Pirolli, and V. Jayasankar Apelin has in vivo inotropic effects on normal and failing hearts Circulation 110 Suppl 11 2004 187 193
41. E.A. Ashley, J. Powers, and M. Chen The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo Cardiovasc Res 65 2005 73 82
42. M. Wang, R.C. Gupta, and S. Rastogi Effects of acute intravenous infusion of apelin on left ventricular function in dogs with advanced heart failure J Card Fail 19 2013 509 516
43. Y.X. Jia, C.S. Pan, and J. Zhang Apelin protects myocardial injury induced by isoproterenol in rats Regul Pept 133 2006 147 154
44. H. Pang, B. Han, T. Yu, and Z. Zong Effect of apelin on the cardiac hemodynamics in hypertensive rats with heart failure Int J Mol Med 34 2014 756 764
45. T. Dai, G. Ramirez-Correa, and W.D. Gao Apelin increases contractility in failing cardiac muscle Eur J Pharmacol 553 2006 222 228
46. M.J. Kleinz, and G.F. Baxter Apelin reduces myocardial reperfusion injury independently of PI3K/Akt and P70S6 kinase Regul Pept 146 2008 271 277
47. P. Atluri, K.J. Morine, and G.P. Liao Ischemic heart failure enhances endogenous myocardial apelin and APJ receptor expression Cell Mol Biol Lett 12 2007 127 138
48. A.Y. Sheikh, H.J. Chun, and A.J. Glassford In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure Am J Physiol Heart Circ Physiol 294 2008 H88 98
49. V.P. Ronkainen, J.J. Ronkainen, and S.L. Hänninen Hypoxia inducible factor regulates the cardiac expression and secretion of apelin FASEB J 21 2007 1821 1830
50. M.A. Mahar, A. Rainio, and M. Ilves Changes in natriuretic peptides, apelin and adrenomedullin after off-pump and on-pump coronary artery bypass surgery J Cardiovasc Surg (Torino) 49 2008 783 791
51. J. Zhang, C.X. Ren, and Y.F. Qi Exercise training promotes expression of apelin and APJ of cardiovascular tissues in spontaneously hypertensive rats Life Sci 79 2006 1153 1159
52. H. Fukushima, N. Kobayashi, H. Takeshima, W. Koguchi, and T. Ishimitsu Effects of olmesartan on apelin/APJ and Akt/eNOS pathway in Dahl rats with end-stage heart failure J Cardiovasc Pharmacol 55 2010 83 88
53. R. AkcIlar, S. Turgut, and V. Caner Apelin effects on blood pressure and RAS in DOCA-salt-induced hypertensive rats Clin Exp Hypertens 35 2013 550 557
54. Y. Iwanaga, Y. Kihara, H. Takenaka, and T. Kita Down-regulation of cardiac apelin system in hypertrophied and failing hearts: possible role of the angiotensin II-angiotensin type I receptor system J Mol Cell Cardiol 41 2006 798 806
55. W. Koguchi, N. Kobayashi, H. Takeshima, M. Ishikawa, F. Sugiyama, and T. Ishimitsu Cardioprotective effect of apelin-13 on cardiac performance and remodeling in end-stage heart failure Circ J 76 2012 137 144
56. M.C. Scimia, C. Hurtado, and S. Ray APJ acts as a dual receptor in cardiac hypertrophy Nature 488 2012 394 398
57. T. Sato, T. Suzuki, and H. Watanabe Apelin is a positive regulator of ACE2 in failing hearts J Clin Invest 123 2013 5203 5211
58. W.W. Hung, T.J. Hsieh, and T. Lin Blockade of the renin-angiotensin system ameliorates apelin production in 3T3-L1 adipocytes Cardiovasc Drugs Ther 25 2011 3 12
59. J.C. Zhong, X.Y. Yu, Y. Huang, L.M. Yung, C.W. Lau, and S.G. Lin Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice Cardiovasc Res 74 2007 388 395
60. K. Siddiquee, J. Hampton, and S. Khan Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production J Hypertens 29 2011 724 731
61. U. Danilczyk, and J.M. Penninger Angiotensin-converting enzyme II in the heart and the kidney Circ Res 98 2006 463 471
62. C. Vickers, P. Hales, and V. Kaushik Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase J Biol Chem 277 2002 14838 14843
63. D.K. Lee, V.R. Saldivia, T. Nguyen, R. Cheng, S.R. George, and B.F. O'Dowd Modification of the terminal residue of apelin-13 antagonizes its hypotensive action Endocrinology 146 2005 231 236
64. S. Epelman, W.H. Tang, S.Y. Chen, F. van Lente, G.S. Francis, and S. Sen Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system J Am Coll Cardiol 52 2008 750 754
65. S. Epelman, K. Shrestha, and R.W. Troughton Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes J Card Fail 15 2009 565 571
66. K.S. Chong, R.S. Gardner, J.J. Morton, E.A. Ashley, and T.A. McDonagh Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure Eur J Heart Fail 8 2006 355 360
67. P. Francia, A. Salvati, and C. Balla Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin Eur J Heart Fail 9 2007 306 309
68. J.P. Goetze, J.F. Rehfeld, and J. Carlsen Apelin: a new plasma marker of cardiopulmonary disease Regul Pept 133 2006 134 138
69. W. Mullens, J. Bartunek, and W.H. Tang Early and late effects of cardiac resynchronization therapy on force-frequency relation and contractility regulating gene expression in heart failure patients Heart Rhythm 5 2008 52 59
70. J.R. Dalzell, C.E. Jackson, K.S. Chong, T.A. McDonagh, and R.S. Gardner Do plasma concentrations of apelin predict prognosis in patients with advanced heart failure? Biomark Med 8 2014 807 813
71. K.H. Miettinen, J. Magga, and O. Vuolteenaho Utility of plasma apelin and other indices of cardiac dysfunction in the clinical assessment of patients with dilated cardiomyopathy Regul Pept 140 2007 178 184
72. R.R. van Kimmenade, J.L. Januzzi Jr., and P.T. Ellinor Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure J Am Coll Cardiol 48 2006 1217 1224
73. M. Przewlocka-Kosmala, T. Kotwica, A. Mysiak, and W. Kosmala Reduced circulating apelin in essential hypertension and its association with cardiac dysfunction J Hypertens 29 2011 971 979
74. S.M. Chandra, H. Razavi, and J. Kim Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension Arterioscler Thromb Vasc Biol 31 2011 814 820
75. P.T. Ellinor, A.F. Low, and C.A. Macrae Reduced apelin levels in lone atrial fibrillation Eur Heart J 27 2006 222 226
76. E.M. Kallergis, E.G. Manios, and E.M. Kanoupakis Effect of sinus rhythm restoration after electrical cardioversion on apelin and brain natriuretic peptide prohormone levels in patients with persistent atrial fibrillation Am J Cardiol 105 2010 90 94
77. S. Helske, P.T. Kovanen, J. Lommi, H. Turto, and M. Kupari Transcardiac gradients of circulating apelin: extraction by normal hearts vs release by hearts failing due to pressure overload J Appl Physiol 109 2010 1744 1748
78. B. Chandrasekaran, P.R. Kalra, J. Donovan, J. Hooper, J.R. Clague, and T.A. McDonagh Myocardial apelin production is reduced in humans with left ventricular systolic dysfunction J Card Fail 16 2010 556 561
79. R.A. Weir, K.S. Chong, and J.R. Dalzell Plasma apelin concentration is depressed following acute myocardial infarction in man Eur J Heart Fail 11 2009 551 558
80. R. Sarzani, C. Forleo, and F. Pietrucci The 212A variant of the APJ receptor gene for the endogenous inotrope apelin is associated with slower heart failure progression in idiopathic dilated cardiomyopathy J Card Fail 13 2007 521 529
81. O. Gualillo, J.R. González-Juanatey, and F. Lago The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives Trends Cardiovasc Med 17 2007 275 283
82. S. von Haehling, E.A. Jankowska, and S.D. Anker Tumour necrosis factor-alpha and the failing heart - pathophysiology and therapeutic implications Basic Res Cardiol 99 2004 18 28
83. K. Higuchi, T. Masaki, and K. Gotoh Apelin, an APJ receptor ligand, regulates body adiposity and favors the messenger ribonucleic acid expression of uncoupling proteins in mice Endocrinology 148 2007 2690 2697
84. M.V. Heinonen, A.K. Purhonen, and P. Miettinen Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding Regul Pept 130 2005 7 13
85. L. Li, G. Yang, and Q. Li Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects Exp Clin Endocrinol Diabetes 114 2006 544 548
86. I. Castan-Laurell, M. Vitkova, and D. Daviaud Effect of hypocaloric diet-induced weight loss in obese women on plasma apelin and adipose tissue expression of apelin and APJ Eur J Endocrinol 158 2008 905 910
87. D. Daviaud, J. Boucher, and S. Gesta TNF alpha up-regulates apelin expression in human and mouse adipose tissue FASEB J 20 2006 1528 1530
88. D.L. Mann, J.J. McMurray, and M. Packer Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) Circulation 109 2004 1594 1602
89. E.S. Chung, M. Packer, K.H. Lo, A.A. Fasanmade, J.T. Willerson Anti-TNF Therapy Against Congestive Heart Failure Investigators Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial Circulation 107 2003 3133 3140
90. M. Cicoira, A.P. Maggioni, R. Latini Val-HeFT Investigators Body mass index, prognosis and mode of death in chronic heart failure: results from the Valsartan Heart Failure Trial Eur J Heart Fail 9 2007 397 402
91. F. Gustafsson, C.B. Kragelund, C. Torp-Pedersen DIAMOND Study Group Effect of obesity and being overweight on long-term mortality in congestive heart failure: influence of left ventricular systolic function Eur Heart J 26 2005 58 64
92. G.C. Fonarow, P. Srikanthan, M.R. Costanzo, G.B. Cintron, M. Lopatin ADHERE Scientific Advisory Committee and Investigators An obesity paradox in acute heart failure: analysis of body mass index and inhospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry Am Heart J 153 2007 74 81
93. S.J. Pocock, J.J. McMurray, J. Dobson CHARM Investigators Weight loss and mortality risk in patients with chronic heart failure in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programme Eur Heart J 29 2008 2641 2650
94. J.R. Teerlink, G. Cotter, B.A. Davison Relaxin in Acute Heart Failure (RELAX-AHF) Investigators Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial Lancet 381 2013 29 39
95. X. Iturrioz, R. Alvear-Perez, and N. De Mota Identification and pharmacological properties of E339-3D6, the first nonpeptidic apelin receptor agonist FASEB J 24 2010 1506 1517
96. J.F. Margathe, X. Iturrioz, and R. Alvear-Perez Structure-activity relationship studies toward the discovery of selective apelin receptor agonists J Med Chem 57 2014 2908 2919
97. J. Hamada, J. Kimura, and J. Ishida Evaluation of novel cyclic analogues of apelin Int J Mol Med 22 2008 547 552